MET and non-small cell lung carcinoma: Similarly, Awad and colleagues (2019) reported on patients with metastatic NSCLC with METex14 skipping alterations; a median survival of 8.1 months was shown for those who did not receive a MET inhibitor (n = 34), and 24.6 months for those who did (95% CI: 12.1, NA) (n = 27) [19].